Testing a New Radiation Technique for Cancer Spread to Soft Tissue
Compares lattice radiation with standard body radiation for breast or lung cancer in soft tissue.
Plain-language title generated from the registry record
Registry title: A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
Key facts
- Where
- Basking Ridge, Commack, Harrison, Middletown, Montvale, New York, and Rockville Centre, United StatesSee the 7 sites
Where in United States
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)Basking Ridge, United StatesTaking people
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)Commack, United StatesTaking people
- Memorial Sloan Kettering Westchester (All Protocol Activities)Harrison, United StatesTaking people
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities)Middletown, United StatesTaking people
- Memorial Sloan Kettering Bergen (Limited Protocol Activities)Montvale, United StatesTaking people
- Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, United StatesTaking people
- Memorial Sloan Kettering Nassau (Limited Protocol Activities)Rockville Centre, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Memorial Sloan Kettering Cancer Center
- Trial code
- NCT05837767
- Record updated
- 2 September 2026
- Original description
The purpose of this study is to find out whether lattice radiation therapy (LRT) is an effective radiation therapy technique when compared to standard stereotactic body radiation therapy (SBRT). The study will also study how the different radiation therapy techniques (LRT and SBRT) affect how many immune cells are able to attack and kill tumor cells (immune infiltration).Read full original descriptionShow less
A Pilot Study of Spatially Fractionated Radiation Therapy in Patients With Extra-Cranial Soft Tissue Metastases
The purpose of this study is to find out whether lattice radiation therapy (LRT) is an effective radiation therapy technique when compared to standard stereotactic body radiation therapy (SBRT). The study will also study how the different radiation therapy techniques (LRT and SBRT) affect how many immune cells are able to attack and kill tumor cells (immune infiltration).
Inclusion: Patients with biopsy confirmed advanced/metastatic solid tumors of the following types: invasive ductal or lobular breast carcinoma (all histological and intrinsic subtypes), non-small cell lung cancer (NSCLC, all subtypes), gastrointestinal squamous cell or adenocarcinomas (including pancreatic cancer), bladder cancer, renal cell carcinoma, melanoma, and soft tissue sarcoma (all subtypes), who require and are being planned for palliative radiation therapy to at least one site of extracranial metastatic disease measuring at least 5 cm in a single axis. If a patient, requires palliative radiotherapy to additional sites, these can be treated with standard of care SBRT per departmental guidelines; Age ≥ 18 years; ECOG Performance Status of 0 or 1.
Exclusion: Prior radiation therapy to the candidate metastatic sites under consideration for treatment ("re-irradiation" is disallowed); Concomitant anti-neoplastic treatment is not allowed during the days of radiation treatment delivery and should be completed or held for 3 days prior to commencement of protocol treatment and for 3 days following completion of radiotherapy, or with resolution of associated acute toxicities; Medical condition such as uncontrolled infection (including HIV), uncontrolled diabetes mellitus, or connective tissue diseases (lupus, systemic sclerosis, or other collagen vascular diseases) that, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient; Patients with a "currently active" metastatic second malignancy; Patients on oral or parental corticosteroids. Physiological doses of steroids are permitted (eg for patients with adrenal insufficiency). If patients are on supraphysiological doses of steroids, these must be discontinued and held during the period of the study; Patients who are pregnant or breastfeeding; Unwilling or unable to participate in all required study evaluations and procedures; Unable to understand the purpose and risks of the study and to provide a signed and dated informed consent form (ICF) and authorization to use protected health information (in accordance with national and local patient privacy regulations).